1. A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30mg and ibuprofen 2400mg for the treatment of patients with osteoarthritis 
A. Puopolo, M.D., J.A. Boice, Ph.D., J.L. Fidelholtz, M.D., T.W. Littlejohn, M.D., P. Miranda, M.D., A. Berrocal, M.D., A. Ko, M.P.H., N. Cichanowitz, M.S.J., A.S. Reicin, M.D. 
Osteoarthritis and Cartilage 
Volume 15, Issue 12, Pages (December 2007)
DOI: /j.joca
Copyright © 2007 Osteoarthritis Research Society International Terms and Conditions

2. Fig. 1
Disposition of patients with OA enrolled in 12-week evaluation of etoricoxib 30mg and ibuprofen 2400mg vs placebo. †: The most common reasons patients were not randomized were due to failure to meet one or more inclusion criteria (i.e., not satisfying flare criteria and having a clinical diagnosis of OA based on clinical and radiographic criteria) or because one or more exclusion criteria were met (i.e., having an abnormal laboratory safety test result). ‡: Other reasons for discontinuation included lost to follow-up; unknown reason; patient moved; patient withdrew consent; and protocol deviation.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2007 Osteoarthritis Research Society International Terms and Conditions

3. Fig. 2
Co-primary endpoints evaluated (0–100mm VAS) over 12-week period of treatment with placebo, etoricoxib 30mg/day, or ibuprofen 2400mg/day in patients with OA of the knee or hip. (a) WOMAC-PS; (b) WOMAC-PFS; (c) PGADS; and (d) pairwise treatment differences (VAS) in co-primary endpoints for patients with OA treated daily with etoricoxib 30mg, ibuprofen 2400mg, or placebo. Note: the week number for each group has been shifted along the horizontal scale to improve legibility. Error bars are standard errors. S=screening and R=randomization.
Osteoarthritis and Cartilage  , DOI: ( /j.joca )
Copyright © 2007 Osteoarthritis Research Society International Terms and Conditions